title: Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria.
abstract: In order to provide effective treatment options for infections caused by multidrug-resistant bacteria, innovative antibiotics are necessary, preferably with novel modes of action and/or belonging to novel classes of drugs. Naturally occurring cyclic lipodepsipeptides, which contain one or more ester bonds along with the amide bonds, have emerged as promising candidates for the development of new antibiotics. Some of these natural products are either already marketed or in advanced stages of clinical development. However, despite the progress in the development of new antibacterial agents, it is inevitable that resistant strains of bacteria will emerge in response to the widespread use of a particular antibiotic and limit its lifetime. Therefore, development of new antibiotics remains our most efficient way to counteract bacterial resistance.
authors.affiliation: Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Post St Lucie, FL 34987, USA.
authors.forename: Nina
authors.initials: N
authors.lastname: Bionda
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Pitteloud
authors.forename: Predrag
authors.initials: P
authors.lastname: Cudic
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D001426:Bacterial Proteins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017576:Daptomycin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D047630:Depsipeptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D047630:Depsipeptides; C099200:fusaricidin A; C041438:ramoplanin; D017576:Daptomycin